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Answers
1. The changes in granulocyte nuclei morphology along
with the presence of immature forms in peripheral blood
(after the exclusion of myelodysplastic syndrome, leuke-
mia, and infection) allowed us to diagnose the pseudo
Pelger–Huët anomaly (PPHA).
2. A unilobed neutrophil in the patient’s peripheral blood.
3. It was decided to administer another dose of rituximab
(Rtx), which resulted in the maintenance of CD20 lym-
phocyte depletion with subsequent remission of the ne-
phrotic syndrome. This also allowed us to terminate cor-
ticosteroid therapy.
Discussion
Pelger–Huët anomaly (PHA) is a very rare, multi-factorial
disorder of granulocytopoiesis that manifests itself in reduced
nuclear segmentation and excessive chromatin condensation
in neutrophils [1–4]. The disease may be hereditary or ac-
quired. The cause of congenital PHA is probably a mutation
in the lamin B receptor (LBR) gene [1]. Presumably, in the
acquired form of PHA, the pseudo-Pelger–Huët anomaly
(PPHA), etiological factors reversibly suppress expression of
the LBR gene and block the functions of the LBR protein [5].
PPHA may occur after the use of certain medications and in
patients who suffer from hematological or infectious disorders
[5]. Owing to the fact that dysgranulopoiesis may be a marker
of a myelodysplastic or myeloproliferative process, the emer-
gence of granulocyte abnormalities in peripheral blood in a
child who has been treated for many years using immunosup-
pressive drugs, should raise great concern regarding neoplas-
tic processes. In differentiating between proliferative disorder
and iatrogenic forms of PPHA, the key elements are: clinical
data, reversibility of the process, assessment of peripheral
blood smear and bone marrow biopsy [5]. It was impossible
for us to establish a final diagnosis without extensive tests.
Initially, both the myelogram and the BCR mutation genetic
test allowed us to reject suspicions of a myeloproliferative
process and myelodysplastic syndrome (MDS). Most of the
reported cases of PPHA refer to patients after vascularized
organ transplantation who receive immunosuppressive
polytherapy (mainly mycophenolate mofetil (MMF) as a basic
drug in the prevention of transplant rejection) [5, 6]. At the
time of the occurrence of dysgranulopoiesis, our patient was at
a critical moment of immunosuppressive therapy conversion.
In the regimen, the patient was receiving a full dose of MMF.
Two weeks prior to the manifestation of PPHA, Rtx was ad-
ministered due to the high frequency of nephrotic syndrome
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relapses. Nephrotic syndrome additionally had features of se-
vere steroid and cyclosporine A (CsA) toxicity apparent both
clinically and microscopically. The dose of MMF was imme-
diately reduced and subsequently withdrawn after the occur-
rence of PPHA, which caused the normalization of complete
blood count (CBC). It is essential to point out the fact that
MMF used in monotherapy did not lead to any morphological
granulocyte changes. Perhaps an explanation of the observed
phenomenon is the pharmacological potentialization of the
effect of given drugs. It may also suggest that MMF, as an
inhibitor of inosine-5′-monophosphate dehydrogenase
(IMPDH), has a myelosuppressive activity [6]. Presumably,
the mechanism leading to the occurrence of PPHA may be
associated with drug interactions or impairment of the func-
tion of enzymes that are involved in the transport and metab-
olism of drugs. There are many hypotheses that suggest a
possible mechanism of an impaired process of granulocyte
nuclei segmentation in PPHA, e.g., individual variation of
IMPDH activity, which has an influence on adverse effects
of MMF [6]. However, the most probable cause of PPHA
seems to be multi-drug interactions [1–5]. Determination of
a main role for one of the drugs in particular is almost impos-
sible. The majority of patients described in publications re-
ceived polytherapy. Despite the fact that in recent brief reports
there is some information regarding the possibility of PPHA
occurrence after Rtx administration, the most probable cause
of the PPHA in this patient was the MMF interactions, since
only total withdrawal of MMF resulted in normalization of
hematopoietic cells.
Conclusions
Combination therapy with the use of MMF and other immu-
nosuppressive or antiviral drugs may probably cause
dysgranulopoiesis in children who are treated due to trans-
plantation and immune-related diseases. Regarding both the
recent report on severe hypogammaglobulinemia incidence
and our experiences with granulocyte nuclei deformation after
the administration ofMMF, it seems rational to understand the
effect of MMF as a multi-level immune system suppression,
especially in extensively applied polytherapy.
To conclude, the case reminds us that during immunosup-
pressive therapy it is essential to remain vigilant and cautious,
due to the fact that the possible occurrence of blood cell ab-
normalities may require the differentiation between relatively
frequent diseases, such as reactive illnesses, proliferative dis-
orders or myelodysplastic syndromes, and uncommon medi-
cal conditions like the PPHA.
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